Biocon Pharma receives Health Canada approval for micafungin injection

Yash Agarwal — Mon, 11 May 2026 03:03:04 +0000

Biocon Pharma Limited, a subsidiary of Biocon Limited, has secured approval from Health Canada for its micafungin for injection, USP, available in 50 mg and 100 mg dosages. This approval marks a significant milestone for the company, expanding its portfolio in the biosimilars and generics market.

The approved micafungin product is designed for use in adults and children aged four months and older. It is indicated for the treatment of patients suffering from Candidemia, Acute Disseminated Candidiasis, Candida Peritonitis, and Abscesses infections. Additionally, it is approved for treating esophageal candidiasis and for the prophylaxis of Candida infections in patients undergoing hematopoietic stem cell transplantation.

This development is expected to bolster Biocon’s position in the integrated biosimilars and generics sector, providing a wider range of treatment options for healthcare providers and patients.

Disclaimer: This article is based on a regulatory filing submitted to the National Stock Exchange of India (NSE).

Biocon Pharma Limited | Business Upturn

Biocon Pharma receives Health Canada approval for micafungin injection